Full Fed. Circ. Told Biogen Ruling Threatens Drug Patents
Pharmaceutical and chemistry groups have urged the full Federal Circuit to review a panel decision invalidating a Biogen patent for lacking an adequate written description, saying it creates an improper new...To view the full article, register now.
Already a subscriber? Click here to view full article